Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.

@article{Burke2012HealthCC,
  title={Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.},
  author={James P. Burke and Robert J. Sanchez and A. V. Joshi and Joseph C. Cappelleri and Mahesh Kulakodlu and Rachel Halpern},
  journal={Pain practice : the official journal of World Institute of Pain},
  year={2012},
  volume={12 3},
  pages={209-18}
}
BACKGROUND Pregabalin and duloxetine are two FDA-approved medications for the treatment of pain associated with diabetic peripheral neuropathy (pDPN). The objective of this study was to compare changes in all-cause and pDPN-related health care costs in patients with pDPN initiated on pregabalin or duloxetine. METHODS Patients at least 18 years of age initiating pregabalin or duloxetine between March 1, 2006 and December 31, 2008 were identified from a large U.S. managed care plan database… CONTINUE READING